Dorash的个人主页 - 老虎社区

Dorash

暂无个人介绍

IP属地：湖北

31关注

2粉丝

0主题

0勋章

2021-03-31

不错

张一鸣内部演讲：字节应该回归 “平常心”

2021-03-24

文章说q1今年收入1千万

Kindred Biosciences (KIN) Reports Q4 Loss, Lags Revenue Estimates

2021-03-24

为啥这两只刚好是我买入的，目前浮亏一成了！

These 2 Penny Stocks Could Rally All the Way to $11, Say Analysts

2020-11-25

$盈透证券(IBKR)$换了工作，结果绑的扣扣邮箱不能换手机号，因为手机已经注销了，然后年底想取钱，结果告知被冻结了，取不出来了。儿子叒生病了，不知道什么时候好，现在回了国外那边邮件，啥时候能把钱转出来呢！大家有这种情况吗？

2020-09-21

本来以为卖了美股就安全了，可是其他a股h也下跌啊

抱歉，原内容已删除

2020-06-08

$枫叶教育(01317)$不错不错，值得关注！

2019-12-11

$中兴通讯(00763)$同为5g概念你为啥不知道涨？看看人家立讯精密！！！

2019-12-11

$小米集团-W(01810)$这种好的有业绩的还有利润的，还是知名的，还在增长的，腰斩就是黄金坑啊！

2019-12-10

$小米集团-W(01810)$K30在哪里买啊？官网还看不到！

2019-12-10

$小米集团-W(01810)$为啥股价还没有起色？

2019-11-26

$老虎证券(TIGR)$买了200股，还没成交

2019-05-23

$特斯拉(TSLA)$ 150我的蚂蚁花呗都要被炸出来了！

2019-05-06

$特斯拉(TSLA)$ 跪求200低吸的机会！赚个40万老子就辞职不干了，妈的！

2019-05-02

$特斯拉(TSLA)$ 融资的费率到底是多少？在哪里查？印象中好像是8%多？请教下大家！

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3464149602391943","uuid":"3464149602391943","gmtCreate":1501055582561,"gmtModify":1502690323634,"name":"Dorash","pinyin":"dorash","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":31,"tweetSize":17,"questionSize":0,"limitLevel":900,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":1,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-4","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"明星虎友","description":"加入老虎社区2000天","bigImgUrl":"https://static.tigerbbs.com/dddf24b906c7011de2617d4fb3f76987","smallImgUrl":"https://static.tigerbbs.com/53d58ad32c97254c6f74db8b97e6ec49","grayImgUrl":"https://static.tigerbbs.com/6304700d92ad91c7a33e2e92ec32ecc1","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.02.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.14","exceedPercentage":"93.27%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.29%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":"湖北","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":354661149,"gmtCreate":1617167599781,"gmtModify":1617167599781,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"不错","listText":"不错","text":"不错","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/354661149","repostId":"1168244531","repostType":2,"repost":{"id":"1168244531","kind":"news","pubTimestamp":1617112248,"share":"https://ttm.financial/m/news/1168244531?lang=&edition=full","pubTime":"2021-03-30 21:50","market":"sh","language":"zh","title":"张一鸣内部演讲：字节应该回归 “平常心”","url":"https://stock-news.laohu8.com/highlight/detail?id=1168244531","media":"晚点LatePost","summary":"今天上午 10 点，字节跳动在启用不到半年的新办公地点北京方恒时尚中心举办九周年庆，张一鸣通过视频直播向全公司发表演讲，主题是平常心。\n字节跳动刚从小米挖来的 CFO 周受资也在活动中首次亮相。但他并","content":"<p>今天上午 10 点，字节跳动在启用不到半年的新办公地点北京方恒时尚中心举办九周年庆，张一鸣通过视频直播向全公司发表演讲，主题是平常心。</p>\n<p>字节跳动刚从小米挖来的 CFO 周受资也在活动中首次亮相。但他并未提到字节的上市计划或估值相关的信息。</p>\n<p>近一小时的主旨演讲中，张一鸣将所有时间用来强调团队应当保持平常心。他认为，团队越急切越紧张效果越不好，只有保持平常心，才能细腻地观察事物，做到不扭曲，定出比较好的目标和策略，做到比较好的执行结果。</p>\n<p>说这话时，根据彭博社本周的报道，字节跳动估值已经达到了 2500 亿美元，比去年 11 月最新一轮融资后高出 700 亿美元，也高于百度和快手市值之和。</p>\n<p>字节员工手里的期权也更值钱了。记者获悉，去年 6 月时，字节跳动回购员工期权的价格是每股 60 美元。11 月的融资后，每股回购价涨至 88 美元。而本月初，回购价格已涨到 180 美元。</p>\n<p>伴随估值提升，不断有字节国内或国际业务拆分上市的消息传出。财富激增的可能性从来都不利于让员工保持平常心。</p>\n<p>但字节的竞争对手比以往更多了。张一鸣称 2020 年是 “加速动态的一年”。一年里，字节增加了 4 万员工，在游戏、电商、教育等领域全线扩张。最近，抖音又开始尝试本地生活广告，进入美团的领地。</p>\n<p>字节今日头条和抖音的用户量增长不可能无限持续。而投入巨大的电商、教育和游戏业务，还没有展现出抖音、头条曾经的增长速度。</p>\n<p>近一小时的演讲中，张一鸣将所有时间用来强调团队应当保持平常心。</p>\n<p><b>有突破的业务：懂车帝、番茄小说、瓜瓜龙等</b></p>\n<p>演讲开始，张一鸣列出有进展的业务包括：懂车帝、番茄小说、头条搜索、瓜瓜龙启蒙、大力智能、飞书、朝夕光年。</p>\n<p>大力智能是字节教育部门的硬件产品，朝夕光年则是字节的游戏研发与发行团队。懂车帝平台内容、瓜瓜龙启蒙获得了用户较高的评价。他对番茄小说的原创内容表达了认可，去年十二月的双月会上，他还称赞过番茄小说的用户增长速度。同时他认为飞书的视频会议功能和头条的搜索功能比刚上线时都有了较大起色。</p>\n<p>字节跳动海外的增长也没有因为特朗普的总统令停下。根据张一鸣展示的增长曲线，即便去掉被封的 TikTok 印度数字，其海外产品日均活跃用户（DAU）增速，依然超过抖音、西瓜、今日头条等产品在中国的表现。</p>\n<p><b>团队应该谨慎下判断</b></p>\n<p>张一鸣说，团队很多时候并不清楚业务为什么增长或下滑。人们往往看到用户增长，就觉得自己做的对，不增长就非常焦虑。“增长可能是 UG（用户增长）花的钱多，可能是疫情隔离，用户降低可能是因为开学，这些和事情的本质没有多大的变化。” 所以增长的真正原因，“我们有时也不清楚。”</p>\n<p>张一鸣认为正确的决策来源于事实的观察，比起 “Rush to conclusion”，员工需要去体验产品、与用户交谈、理解自己的对手和处境，他举了两个字节早期的例子：</p>\n<p>在 2015 年前后、抖音还没上线时，字节内部曾讨论，快手是不是中国的 Instagram。但回头看，他觉得还是应该理解用户为什么用快手，而不是给它下定义。</p>\n<p>刚开始做抖音时，张一鸣和团队都相信城市用户留存不好的原因是，“白领脑力劳动多，不太会表演”。而 Musical.ly 的创始人 Alex 朱骏也认为，“中国（城市用户）工作多，压力大，没有时间表演”，并因此选择从美国起步。但现在来看，结果完全不是如此。</p>\n<p><b>团队不应该过度关注竞争</b></p>\n<p>随着字节进入越来越多的领域，它也有了越来越多的竞争对手。张一鸣称竞争对手就像蓝军，是参照。但他也警告说，竞争压力可能导致的行为变形，公司和员工被 “竞争干扰了注意力，内心被对于竞争的担忧占据了，” 反而做出了错误的决定。</p>\n<p>他用自己曾经任职的微软举例。微软的主要商业模式是服务企业客户，但 Google 崛起后，微软在浏览器、手机操作系统和 Google 全面竞争。此间，亚马逊悄悄孵化了针对企业的云计算生意，当微软回过神来，已经追赶不上。</p>\n<p><b>要有耐心做更伟大的产品</b></p>\n<p>压力之下，他希望员工能沉下心，换一种方式看待字节的产品，他举出了三个产品作为参照：Google Earth、Scratch（儿童编程软件）、Roblox（沙盒游戏）。这些产品不一定赚钱，但是 “有意思并且很伟大 “。他希望员工能 “remain grounded, keep aiming higher”.</p>\n<p>这三个产品的历史都比字节久远地多。Scratch 和 Roblox 都始于 2006 年，Google Earth 始于 2001 年。Scratch 是麻省理工媒介实验室开发的可视化儿童编程平台，产品开源免费。当中只有 Roblox 获得丰厚商业回报（去年收入 9.2 亿美元）。</p>\n<p><b>不要随便说 All In</b></p>\n<p>字节 2020 年收入超过 2200 亿元人民币，大约是百度的两倍。在讲话中，张一鸣提醒团队，在有资源之后，也不应轻易加杠杆，在错误的方向大投入。“很多公司，包括创业公司，会说咱们是不是就抓住这个机会、赌一把，All In。我自己觉得，随便说 All In 的公司有很大问题。“他认为，想要 All in 换句话说就是 “我不想了，就这样赌一把。”</p>\n<p><b>不要给自己打标签</b></p>\n<p>张一鸣提到了自己对 “打工人” 标签的反感。他认为设标签其实是对自身设限。他回忆自己的早期经历，说自己经常是 “老板不急，我急”，会做很多不在工作范围内的事情，并因此得到成长。</p>\n<p><b>说人话，不要用 fancy 的文档</b></p>\n<p>“过去我们主要靠推荐技术赋予的信息分发能力，跨端联动头抖西多个产品自研，实现深度共建，形成组合拳，打造内容生态闭环，以此赋能客户、用户，创造价值。未来我们要增加横向不同场景的价值，延长服务链路。”</p>\n<p>这是张一鸣在现场读的一段字节双月会的记录，作为不说人话的反面例子。他观察到，自己的内部的报告中，这种方法论、词汇越来越多。</p>\n<p>报告堆砌术语是典型的官僚作风。就像演讲中举的大部分例子一样，张一鸣一次次提醒自己的 10 万员工，不要患上大公司病，要在没有终止的竞争中保持活力。</p>","source":"wandian","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>张一鸣内部演讲：字节应该回归 “平常心”  </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n张一鸣内部演讲：字节应该回归 “平常心”  \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-30 21:50 北京时间&nbsp;&nbsp;&nbsp;<a href=https://mp.weixin.qq.com/s?__biz=MzU3Mjk1OTQ0Ng==&mid=2247487970&idx=2&sn=08a8a4ec6c55cf4fbd25e4d50d78372e&chksm=fcc9ae5bcbbe274d203bf6999b9710ea6c6158def681e05a2c0815d173ac069cf02e3016bd6c&scene=0&xtrack=1><strong>晚点LatePost</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>今天上午 10 点，字节跳动在启用不到半年的新办公地点北京方恒时尚中心举办九周年庆，张一鸣通过视频直播向全公司发表演讲，主题是平常心。\n字节跳动刚从小米挖来的 CFO 周受资也在活动中首次亮相。但他并未提到字节的上市计划或估值相关的信息。\n近一小时的主旨演讲中，张一鸣将所有时间用来强调团队应当保持平常心。他认为，团队越急切越紧张效果越不好，只有保持平常心，才能细腻地观察事物，做到不扭曲，定出比较好...</p>\n\n<a href=\"https://mp.weixin.qq.com/s?__biz=MzU3Mjk1OTQ0Ng==&mid=2247487970&idx=2&sn=08a8a4ec6c55cf4fbd25e4d50d78372e&chksm=fcc9ae5bcbbe274d203bf6999b9710ea6c6158def681e05a2c0815d173ac069cf02e3016bd6c&scene=0&xtrack=1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/fc0d9459911bfb890663ce7587256aa0","relate_stocks":{},"source_url":"https://mp.weixin.qq.com/s?__biz=MzU3Mjk1OTQ0Ng==&mid=2247487970&idx=2&sn=08a8a4ec6c55cf4fbd25e4d50d78372e&chksm=fcc9ae5bcbbe274d203bf6999b9710ea6c6158def681e05a2c0815d173ac069cf02e3016bd6c&scene=0&xtrack=1","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1168244531","content_text":"今天上午 10 点，字节跳动在启用不到半年的新办公地点北京方恒时尚中心举办九周年庆，张一鸣通过视频直播向全公司发表演讲，主题是平常心。\n字节跳动刚从小米挖来的 CFO 周受资也在活动中首次亮相。但他并未提到字节的上市计划或估值相关的信息。\n近一小时的主旨演讲中，张一鸣将所有时间用来强调团队应当保持平常心。他认为，团队越急切越紧张效果越不好，只有保持平常心，才能细腻地观察事物，做到不扭曲，定出比较好的目标和策略，做到比较好的执行结果。\n说这话时，根据彭博社本周的报道，字节跳动估值已经达到了 2500 亿美元，比去年 11 月最新一轮融资后高出 700 亿美元，也高于百度和快手市值之和。\n字节员工手里的期权也更值钱了。记者获悉，去年 6 月时，字节跳动回购员工期权的价格是每股 60 美元。11 月的融资后，每股回购价涨至 88 美元。而本月初，回购价格已涨到 180 美元。\n伴随估值提升，不断有字节国内或国际业务拆分上市的消息传出。财富激增的可能性从来都不利于让员工保持平常心。\n但字节的竞争对手比以往更多了。张一鸣称 2020 年是 “加速动态的一年”。一年里，字节增加了 4 万员工，在游戏、电商、教育等领域全线扩张。最近，抖音又开始尝试本地生活广告，进入美团的领地。\n字节今日头条和抖音的用户量增长不可能无限持续。而投入巨大的电商、教育和游戏业务，还没有展现出抖音、头条曾经的增长速度。\n近一小时的演讲中，张一鸣将所有时间用来强调团队应当保持平常心。\n有突破的业务：懂车帝、番茄小说、瓜瓜龙等\n演讲开始，张一鸣列出有进展的业务包括：懂车帝、番茄小说、头条搜索、瓜瓜龙启蒙、大力智能、飞书、朝夕光年。\n大力智能是字节教育部门的硬件产品，朝夕光年则是字节的游戏研发与发行团队。懂车帝平台内容、瓜瓜龙启蒙获得了用户较高的评价。他对番茄小说的原创内容表达了认可，去年十二月的双月会上，他还称赞过番茄小说的用户增长速度。同时他认为飞书的视频会议功能和头条的搜索功能比刚上线时都有了较大起色。\n字节跳动海外的增长也没有因为特朗普的总统令停下。根据张一鸣展示的增长曲线，即便去掉被封的 TikTok 印度数字，其海外产品日均活跃用户（DAU）增速，依然超过抖音、西瓜、今日头条等产品在中国的表现。\n团队应该谨慎下判断\n张一鸣说，团队很多时候并不清楚业务为什么增长或下滑。人们往往看到用户增长，就觉得自己做的对，不增长就非常焦虑。“增长可能是 UG（用户增长）花的钱多，可能是疫情隔离，用户降低可能是因为开学，这些和事情的本质没有多大的变化。” 所以增长的真正原因，“我们有时也不清楚。”\n张一鸣认为正确的决策来源于事实的观察，比起 “Rush to conclusion”，员工需要去体验产品、与用户交谈、理解自己的对手和处境，他举了两个字节早期的例子：\n在 2015 年前后、抖音还没上线时，字节内部曾讨论，快手是不是中国的 Instagram。但回头看，他觉得还是应该理解用户为什么用快手，而不是给它下定义。\n刚开始做抖音时，张一鸣和团队都相信城市用户留存不好的原因是，“白领脑力劳动多，不太会表演”。而 Musical.ly 的创始人 Alex 朱骏也认为，“中国（城市用户）工作多，压力大，没有时间表演”，并因此选择从美国起步。但现在来看，结果完全不是如此。\n团队不应该过度关注竞争\n随着字节进入越来越多的领域，它也有了越来越多的竞争对手。张一鸣称竞争对手就像蓝军，是参照。但他也警告说，竞争压力可能导致的行为变形，公司和员工被 “竞争干扰了注意力，内心被对于竞争的担忧占据了，” 反而做出了错误的决定。\n他用自己曾经任职的微软举例。微软的主要商业模式是服务企业客户，但 Google 崛起后，微软在浏览器、手机操作系统和 Google 全面竞争。此间，亚马逊悄悄孵化了针对企业的云计算生意，当微软回过神来，已经追赶不上。\n要有耐心做更伟大的产品\n压力之下，他希望员工能沉下心，换一种方式看待字节的产品，他举出了三个产品作为参照：Google Earth、Scratch（儿童编程软件）、Roblox（沙盒游戏）。这些产品不一定赚钱，但是 “有意思并且很伟大 “。他希望员工能 “remain grounded, keep aiming higher”.\n这三个产品的历史都比字节久远地多。Scratch 和 Roblox 都始于 2006 年，Google Earth 始于 2001 年。Scratch 是麻省理工媒介实验室开发的可视化儿童编程平台，产品开源免费。当中只有 Roblox 获得丰厚商业回报（去年收入 9.2 亿美元）。\n不要随便说 All In\n字节 2020 年收入超过 2200 亿元人民币，大约是百度的两倍。在讲话中，张一鸣提醒团队，在有资源之后，也不应轻易加杠杆，在错误的方向大投入。“很多公司，包括创业公司，会说咱们是不是就抓住这个机会、赌一把，All In。我自己觉得，随便说 All In 的公司有很大问题。“他认为，想要 All in 换句话说就是 “我不想了，就这样赌一把。”\n不要给自己打标签\n张一鸣提到了自己对 “打工人” 标签的反感。他认为设标签其实是对自身设限。他回忆自己的早期经历，说自己经常是 “老板不急，我急”，会做很多不在工作范围内的事情，并因此得到成长。\n说人话，不要用 fancy 的文档\n“过去我们主要靠推荐技术赋予的信息分发能力，跨端联动头抖西多个产品自研，实现深度共建，形成组合拳，打造内容生态闭环，以此赋能客户、用户，创造价值。未来我们要增加横向不同场景的价值，延长服务链路。”\n这是张一鸣在现场读的一段字节双月会的记录，作为不说人话的反面例子。他观察到，自己的内部的报告中，这种方法论、词汇越来越多。\n报告堆砌术语是典型的官僚作风。就像演讲中举的大部分例子一样，张一鸣一次次提醒自己的 10 万员工，不要患上大公司病，要在没有终止的竞争中保持活力。","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":2138,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":351885004,"gmtCreate":1616584915408,"gmtModify":1616584915408,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"文章说q1今年收入1千万","listText":"文章说q1今年收入1千万","text":"文章说q1今年收入1千万","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/351885004","repostId":"2120700679","repostType":2,"repost":{"id":"2120700679","kind":"news","pubTimestamp":1615930509,"share":"https://ttm.financial/m/news/2120700679?lang=&edition=full","pubTime":"2021-03-17 05:35","market":"us","language":"en","title":"Kindred Biosciences (KIN) Reports Q4 Loss, Lags Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2120700679","media":"Zacks","summary":"Kindred Biosciences (KIN) came out with a quarterly loss of $0.28 per share versus the Zacks Consens","content":"<html><body><p>Kindred Biosciences (KIN) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.40 per share a year ago. These figures are adjusted for non-recurring items.</p>\n<p>This quarterly report represents an earnings surprise of 15.15%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.31 per share when it actually produced a loss of $0.31, delivering no surprise.</p>\n<p>Over the last four quarters, the company has surpassed consensus EPS estimates two times.</p>\n<p>Kindred Bio, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.95 million for the quarter ended December 2020, missing the Zacks Consensus Estimate by 0.94%. This compares to year-ago revenues of $1.4 million. The company has topped consensus revenue estimates two times over the last four quarters.</p>\n<p>The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.</p>\n<p>Kindred Bio shares have added about 13.7% since the beginning of the year versus the S&amp;P 500's gain of 5%.</p>\n<p><b>What's Next for Kindred Bio?</b></p>\n<p>While Kindred Bio has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?</p>\n<p>There are no easy answers to this key question, but <a href=\"https://laohu8.com/S/AONE\">one</a> reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.</p>\n<p>Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.</p>\n<p>Ahead of this earnings release, the estimate revisions trend for Kindred Bio was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.</p>\n<p>It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.33 on $11.9 million in revenues for the coming quarter and -$1.14 on $41.2 million in revenues for the current fiscal year.</p>\n<p>Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 29% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.</p>\n<br/>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. \nClick to get this free report\n<br/> \n<br/>\n<a href=\"https://laohu8.com/S/KIN\">Kindred Biosciences, Inc.</a> (KIN) : Free Stock Analysis Report\n<br/> \n<br/>\nTo read this article on Zacks.com click here.\n<br/> \n<br/>\nZacks Investment Research</body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kindred Biosciences (KIN) Reports Q4 Loss, Lags Revenue Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKindred Biosciences (KIN) Reports Q4 Loss, Lags Revenue Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-17 05:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/kindred-biosciences-kin-reports-q4-213509431.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Kindred Biosciences (KIN) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.40 per share a year ago. These figures ...</p>\n\n<a href=\"https://finance.yahoo.com/news/kindred-biosciences-kin-reports-q4-213509431.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/88Fg6KE6GPnh0zlh3tqRTA--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/9naTdeJlVMX28sdlDpLdrQ--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ac90b3d74679f6d01a122aa033d8a9a4","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/kindred-biosciences-kin-reports-q4-213509431.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2120700679","content_text":"Kindred Biosciences (KIN) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.40 per share a year ago. These figures are adjusted for non-recurring items.\nThis quarterly report represents an earnings surprise of 15.15%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.31 per share when it actually produced a loss of $0.31, delivering no surprise.\nOver the last four quarters, the company has surpassed consensus EPS estimates two times.\nKindred Bio, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.95 million for the quarter ended December 2020, missing the Zacks Consensus Estimate by 0.94%. This compares to year-ago revenues of $1.4 million. The company has topped consensus revenue estimates two times over the last four quarters.\nThe sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.\nKindred Bio shares have added about 13.7% since the beginning of the year versus the S&P 500's gain of 5%.\nWhat's Next for Kindred Bio?\nWhile Kindred Bio has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?\nThere are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.\nEmpirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.\nAhead of this earnings release, the estimate revisions trend for Kindred Bio was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.\nIt will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.33 on $11.9 million in revenues for the coming quarter and -$1.14 on $41.2 million in revenues for the current fiscal year.\nInvestors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 29% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. \nClick to get this free report\n \n\nKindred Biosciences, Inc. (KIN) : Free Stock Analysis Report\n \n\nTo read this article on Zacks.com click here.\n \n\nZacks Investment Research","news_type":1,"symbols_score_info":{"KIN":1}},"isVote":1,"tweetType":1,"viewCount":2225,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":351083321,"gmtCreate":1616545959663,"gmtModify":1616545959663,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"为啥这两只刚好是我买入的，目前浮亏一成了！","listText":"为啥这两只刚好是我买入的，目前浮亏一成了！","text":"为啥这两只刚好是我买入的，目前浮亏一成了！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/351083321","repostId":"2107260553","repostType":2,"repost":{"id":"2107260553","kind":"news","pubTimestamp":1611851471,"share":"https://ttm.financial/m/news/2107260553?lang=&edition=full","pubTime":"2021-01-29 00:31","market":"us","language":"en","title":"These 2 Penny Stocks Could Rally All the Way to $11, Say Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2107260553","media":"TipRanks","summary":"At its January FOMC meeting, the Federal Reserve held interest rates steady – they are near rock-bot","content":"<div>\n<p>At its January FOMC meeting, the Federal Reserve held interest rates steady – they are near rock-bottom now, and to no one’s surprise, the Fed is keeping them there.\nFed Chairman Jerome Powell may ...</p>\n\n<a href=\"https://finance.yahoo.com/news/2-penny-stocks-could-rally-163111780.html\">Web Link</a>\n\n</div>\n","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These 2 Penny Stocks Could Rally All the Way to $11, Say Analysts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese 2 Penny Stocks Could Rally All the Way to $11, Say Analysts\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-01-29 00:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/2-penny-stocks-could-rally-163111780.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>At its January FOMC meeting, the Federal Reserve held interest rates steady – they are near rock-bottom now, and to no one’s surprise, the Fed is keeping them there.\nFed Chairman Jerome Powell may ...</p>\n\n<a href=\"https://finance.yahoo.com/news/2-penny-stocks-could-rally-163111780.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/94euyTCm3Fsmi1L1JkZXKQ--~B/aD00NTc7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/G1wIt1b2ALiEE..QV7lnrw--~B/aD00NTc7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/tipranks_452/24d79aa4d3847ec06a89abac7fdc7612","relate_stocks":{"BLRX":"BioLine Rx"},"source_url":"https://finance.yahoo.com/news/2-penny-stocks-could-rally-163111780.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2107260553","content_text":"At its January FOMC meeting, the Federal Reserve held interest rates steady – they are near rock-bottom now, and to no one’s surprise, the Fed is keeping them there.\nFed Chairman Jerome Powell may have fed some market pessimism when he spoke after the meeting, and pointed out that unemployment, which has been rising in recent months. For market watchers seeking support, there is solace in the Fed’s monetary policy. The central bank is committed to buying $80 billion monthly in Treasury notes, and has put a rate increase on hold, likely until 2023.\nAt least one top strategist sees the current market environment in terms of opportunity. JPMorgan strategist Marko Kolanovic takes a bullish stance, writing, “We expect the global COVID pandemic to decline rapidly in the coming weeks. In fact, the pace of decline in new cases over the last 2 weeks is the highest on record both in the US and globally… Central Banks should remain accommodative given the elevated unemployment levels and over a decade of low inflation running below their targets… Short-term turmoil, such as the one this week, are opportunities to rotate from bonds to equities.”\nTaking this outlook into consideration, we set out to find exciting opportunities that won’t break the bank, namely penny stocks. These stocks, priced at $5 or less, offer investors some of the highest growth potential available in the market. There is risk here, too, as the ‘pennies’ are often priced low for a reason, so due diligence is essential.\nUsing TipRanks’ database, we identified two penny stocks that have earned a “Strong Buy” consensus rating from the analyst community. Not to mention each offers up massive upside potential, as some analysts seem them climbing to $11.\nBioLineRx, Ltd. (BLRX)\nWe’ll start with BioLineRx, a clinical stage biopharma company focused on developing new cancer treatments. Oncology is a major field for cutting edge biopharmas. Cancer is frequently deadly, and frequently resistant to current treatments – and those treatments themselves will frequently cause severe side effects in patients. BioLineRx has an active pipeline of drug candidates, but the most advanced is motixafortide, a synthetic peptide which has completed patient enrollment in a Phase 3 study on stem cell mobilization for autologous bone-marrow transplantation.\nThe drug is being studied for its efficacy in promoting the harvesting of bone marrow prior to the cancer treatment. Results from a pre-planned interim analysis showed ‘statistically significant evidence favoring treatment with motixafortide in the primary endpoint,’ evidence which was so significant that the enrollment was completed early, with 122 patients instead of 177. Stem cell mobilization, using motixafortide, is seen as the company’s most efficient path to registering the new drug for regulatory approval.\nBased on the potential of motixafortide and the $2.40 share price, some analysts think that now is the time to pull the trigger.\nCovering BLRX for Oppenheimer, 5-star analyst Mark Breidenbach noted, “Our thesis remains centered on motixafortide in stem cell mobilization, and we see a disconnect between the company’s market capitalization and motixafortide’s market opportunity as a stem cell mobilizer. Key GENESIS secondary endpoints are expected by mid-2021, and we see little risk heading into these data…”\nThe analyst added, “We believe results from the Phase 3 GENESIS trial could spur the majority of transplant physicians to choose BL-8040 over Mozobil to combine with G-CSF if the drug is approved. Upside to our thesis includes BL-8040 for use in other auto-HSCTs, allo-HSCTs, AML, and solid tumors. The company boasts a catalyst-rich, deep oncology pipeline that has attracted collaborations with Novartis, Merck, and Genentech.”\nGiven all of the above, Breidenbach rates BLRX as a Buy, and his $11 price target suggests a whopping 358% upside for the year ahead. (To watch Breidenbach’s track record, click here)\nThe rest of the Street appears to echo Breidenbach’s bullish sentiment. As it has racked up 3 Buys and no Holds or Sells, the consensus is unanimous: BLRX is a Strong Buy. Adding to the good news, the upside potential lands at ~428% based on the $12.67 average price target. (See BLRX stock analysis on TipRanks)\n\n\n\n\n\nKindred Biosciences (KIN)\nWhile most biotech companies focus on human medications, we are not the only market. Kindred biosciences is biopharmaceutical company in the veterinary market, developing biologic medications to improve the lives of our pets and working animals. The company describes its mission as ‘[bringing] to pets the same kinds of safe and effective medicines that human family members enjoy.’\nParvovirus (CPV) is a highly infectious, and highly lethal, viral disease affecting dogs. While vaccines are available, untreated cases can see upwards of 91% mortality. Kindred’s main pipeline drug, KIND-030 is under development as a treatment for this disease.\nCurrently, the drug candidate is following two paths in the development process – one for treatment of established infections, and one as a prophylactic preventative treatment for CPV. The prophylactic study has shown positive results, with treated dogs all avoiding infection, while all dogs in the placebo group developed parvovirus disease. KIND-030 also showed a mortality benefit when given as a treatment for infection. The drug candidate is in the pivotal study stage of development, the last before potential approval.\nLast month, Kindred announced that it had entered an agreement with Elanco Animal Health – a major manufacturer of veterinary medicines – for production of KIND-030.\nCantor analyst Brandon Folkes sees plenty of potential in Kindred, especially in the company’s agreement with Elanco.\n“A partnership with a leading animal health company, in this case Elanco, is exactly what the company needed, in our view. In our view, this validates KIN's new strategic approach, as a developer of drugs while seeking larger commercial partners. We believe that today's deal should reinforce to investors that there remains meaningful value in Kindred's pipeline, which could be realized over the next 12 to 18 months,” Folkes opined.\nKindred is also conducting studies of Tirnovetmab, or KIND-016, an antibody targeting IL31, in the treatment of atopic dermatitis in dogs. The pivotal efficacy study of this drug started in the last quarter of 2020. There is a potentially huge market for a successful dermatitis treatment for canines; in the last six years, there has been a 47% increase in vet visits for dogs with severe itchy skin, and the market is estimated at $900 million or more.\n“While 2020 has been a tough year for KIN stock, the company continues to have multiple shots on goal from its diversified pipeline that could reward investors from the current levels. With multiple readouts in 2021, and the renewed sole focus on development of its pipeline we expect 2021 could be a banner year for KIN should it be able to deliver on the promise of its pipeline, and in particular the atopic dermatitis portfolio,” the analyst summed up.\nTo this end, Folkes gives KIN an $11 price target, implying a 139% upside potential for 2021, and an Overweight (i.e. Buy) rating. (To watch Folkes’ track record, click here)\nKindred is another company with a unanimous Strong Buy analyst consensus, this one based on 5 recent Buy reviews. The stock has an average price target of $10.25, which suggests room for ~124% growth from the current trading price of $4.59. (See KIN stock analysis on TipRanks)\n\n\n\n\n\nTo find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.\nDisclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.","news_type":1,"symbols_score_info":{"BLRX":0.6,"KIN":0.9}},"isVote":1,"tweetType":1,"viewCount":2813,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":393155907,"gmtCreate":1606265652809,"gmtModify":1703842128908,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/IBKR\">$盈透证券(IBKR)$</a>换了工作，结果绑的扣扣邮箱不能换手机号，因为手机已经注销了，然后年底想取钱，结果告知被冻结了，取不出来了。儿子叒生病了，不知道什么时候好，现在回了国外那边邮件，啥时候能把钱转出来呢！大家有这种情况吗？","listText":"<a href=\"https://laohu8.com/S/IBKR\">$盈透证券(IBKR)$</a>换了工作，结果绑的扣扣邮箱不能换手机号，因为手机已经注销了，然后年底想取钱，结果告知被冻结了，取不出来了。儿子叒生病了，不知道什么时候好，现在回了国外那边邮件，啥时候能把钱转出来呢！大家有这种情况吗？","text":"$盈透证券(IBKR)$换了工作，结果绑的扣扣邮箱不能换手机号，因为手机已经注销了，然后年底想取钱，结果告知被冻结了，取不出来了。儿子叒生病了，不知道什么时候好，现在回了国外那边邮件，啥时候能把钱转出来呢！大家有这种情况吗？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/393155907","isVote":1,"tweetType":1,"viewCount":5435,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3502195913108179","authorId":"3502195913108179","name":"武贤普","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":1,"idStr":"3502195913108179","authorIdStr":"3502195913108179"},"content":"转出来了吗","text":"转出来了吗","html":"转出来了吗"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":975665311,"gmtCreate":1600691907433,"gmtModify":1703822109336,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"本来以为卖了美股就安全了，可是其他a股h也下跌啊","listText":"本来以为卖了美股就安全了，可是其他a股h也下跌啊","text":"本来以为卖了美股就安全了，可是其他a股h也下跌啊","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/975665311","repostId":"1124902004","repostType":4,"isVote":1,"tweetType":1,"viewCount":2986,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":956339198,"gmtCreate":1591574003714,"gmtModify":1704195947188,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/01317\">$枫叶教育(01317)$</a>不错不错，值得关注！","listText":"<a href=\"https://laohu8.com/S/01317\">$枫叶教育(01317)$</a>不错不错，值得关注！","text":"$枫叶教育(01317)$不错不错，值得关注！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/956339198","isVote":1,"tweetType":1,"viewCount":1999,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":910518949,"gmtCreate":1576044352981,"gmtModify":1704271128751,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/00763\">$中兴通讯(00763)$</a>同为5g概念你为啥不知道涨？看看人家立讯精密！！！","listText":"<a href=\"https://laohu8.com/S/00763\">$中兴通讯(00763)$</a>同为5g概念你为啥不知道涨？看看人家立讯精密！！！","text":"$中兴通讯(00763)$同为5g概念你为啥不知道涨？看看人家立讯精密！！！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/910518949","isVote":1,"tweetType":1,"viewCount":4174,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3537045207544484","authorId":"3537045207544484","name":"27个优质股","avatar":"https://static.tigerbbs.com/fde1daa28cae792e520759bac55bcdd3","crmLevel":2,"crmLevelSwitch":0,"idStr":"3537045207544484","authorIdStr":"3537045207544484"},"content":"大家的所属领域不同，立讯精密是零配件处在行业的顶端，中兴通讯是成品是通信应用处于行业的中游","text":"大家的所属领域不同，立讯精密是零配件处在行业的顶端，中兴通讯是成品是通信应用处于行业的中游","html":"大家的所属领域不同，立讯精密是零配件处在行业的顶端，中兴通讯是成品是通信应用处于行业的中游"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":910599969,"gmtCreate":1576035300951,"gmtModify":1704271093586,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$</a>这种好的有业绩的还有利润的，还是知名的，还在增长的，腰斩就是黄金坑啊！","listText":"<a href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$</a>这种好的有业绩的还有利润的，还是知名的，还在增长的，腰斩就是黄金坑啊！","text":"$小米集团-W(01810)$这种好的有业绩的还有利润的，还是知名的，还在增长的，腰斩就是黄金坑啊！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":1,"link":"https://laohu8.com/post/910599969","isVote":1,"tweetType":1,"viewCount":4033,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":910208675,"gmtCreate":1575964746197,"gmtModify":1704730216785,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$</a>K30在哪里买啊？官网还看不到！","listText":"<a href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$</a>K30在哪里买啊？官网还看不到！","text":"$小米集团-W(01810)$K30在哪里买啊？官网还看不到！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/910208675","isVote":1,"tweetType":1,"viewCount":3288,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":910208155,"gmtCreate":1575964724877,"gmtModify":1704730216094,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$</a>为啥股价还没有起色？","listText":"<a href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$</a>为啥股价还没有起色？","text":"$小米集团-W(01810)$为啥股价还没有起色？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/910208155","isVote":1,"tweetType":1,"viewCount":2079,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":937367307,"gmtCreate":1574768576709,"gmtModify":1704728473836,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a>买了200股，还没成交","listText":"<a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a>买了200股，还没成交","text":"$老虎证券(TIGR)$买了200股，还没成交","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/937367307","isVote":1,"tweetType":1,"viewCount":3306,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3478324697411284","authorId":"3478324697411284","name":"超股","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"idStr":"3478324697411284","authorIdStr":"3478324697411284"},"content":"你还看好这只股？？","text":"你还看好这只股？？","html":"你还看好这只股？？"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":906921608,"gmtCreate":1558589407404,"gmtModify":1704696895863,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"$特斯拉(TSLA)$ 150我的蚂蚁花呗都要被炸出来了！","listText":"$特斯拉(TSLA)$ 150我的蚂蚁花呗都要被炸出来了！","text":"$特斯拉(TSLA)$ 150我的蚂蚁花呗都要被炸出来了！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/906921608","isVote":1,"tweetType":1,"viewCount":3285,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":903231895,"gmtCreate":1557116752217,"gmtModify":1704801797526,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"$特斯拉(TSLA)$ 跪求200低吸的机会！赚个40万老子就辞职不干了，妈的！","listText":"$特斯拉(TSLA)$ 跪求200低吸的机会！赚个40万老子就辞职不干了，妈的！","text":"$特斯拉(TSLA)$ 跪求200低吸的机会！赚个40万老子就辞职不干了，妈的！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/903231895","isVote":1,"tweetType":1,"viewCount":6503,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":903994963,"gmtCreate":1556785820852,"gmtModify":1704801148167,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"$特斯拉(TSLA)$ 融资的费率到底是多少？在哪里查？印象中好像是8%多？请教下大家！","listText":"$特斯拉(TSLA)$ 融资的费率到底是多少？在哪里查？印象中好像是8%多？请教下大家！","text":"$特斯拉(TSLA)$ 融资的费率到底是多少？在哪里查？印象中好像是8%多？请教下大家！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/903994963","isVote":1,"tweetType":1,"viewCount":2275,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":903231895,"gmtCreate":1557116752217,"gmtModify":1704801797526,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"$特斯拉(TSLA)$ 跪求200低吸的机会！赚个40万老子就辞职不干了，妈的！","listText":"$特斯拉(TSLA)$ 跪求200低吸的机会！赚个40万老子就辞职不干了，妈的！","text":"$特斯拉(TSLA)$ 跪求200低吸的机会！赚个40万老子就辞职不干了，妈的！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/903231895","isVote":1,"tweetType":1,"viewCount":6503,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":910599969,"gmtCreate":1576035300951,"gmtModify":1704271093586,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$</a>这种好的有业绩的还有利润的，还是知名的，还在增长的，腰斩就是黄金坑啊！","listText":"<a href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$</a>这种好的有业绩的还有利润的，还是知名的，还在增长的，腰斩就是黄金坑啊！","text":"$小米集团-W(01810)$这种好的有业绩的还有利润的，还是知名的，还在增长的，腰斩就是黄金坑啊！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":1,"link":"https://laohu8.com/post/910599969","isVote":1,"tweetType":1,"viewCount":4033,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":393155907,"gmtCreate":1606265652809,"gmtModify":1703842128908,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/IBKR\">$盈透证券(IBKR)$</a>换了工作，结果绑的扣扣邮箱不能换手机号，因为手机已经注销了，然后年底想取钱，结果告知被冻结了，取不出来了。儿子叒生病了，不知道什么时候好，现在回了国外那边邮件，啥时候能把钱转出来呢！大家有这种情况吗？","listText":"<a href=\"https://laohu8.com/S/IBKR\">$盈透证券(IBKR)$</a>换了工作，结果绑的扣扣邮箱不能换手机号，因为手机已经注销了，然后年底想取钱，结果告知被冻结了，取不出来了。儿子叒生病了，不知道什么时候好，现在回了国外那边邮件，啥时候能把钱转出来呢！大家有这种情况吗？","text":"$盈透证券(IBKR)$换了工作，结果绑的扣扣邮箱不能换手机号，因为手机已经注销了，然后年底想取钱，结果告知被冻结了，取不出来了。儿子叒生病了，不知道什么时候好，现在回了国外那边邮件，啥时候能把钱转出来呢！大家有这种情况吗？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/393155907","isVote":1,"tweetType":1,"viewCount":5435,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3502195913108179","authorId":"3502195913108179","name":"武贤普","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":1,"idStr":"3502195913108179","authorIdStr":"3502195913108179"},"content":"转出来了吗","text":"转出来了吗","html":"转出来了吗"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":910208675,"gmtCreate":1575964746197,"gmtModify":1704730216785,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$</a>K30在哪里买啊？官网还看不到！","listText":"<a href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$</a>K30在哪里买啊？官网还看不到！","text":"$小米集团-W(01810)$K30在哪里买啊？官网还看不到！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/910208675","isVote":1,"tweetType":1,"viewCount":3288,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":937367307,"gmtCreate":1574768576709,"gmtModify":1704728473836,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a>买了200股，还没成交","listText":"<a href=\"https://laohu8.com/S/TIGR\">$老虎证券(TIGR)$</a>买了200股，还没成交","text":"$老虎证券(TIGR)$买了200股，还没成交","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/937367307","isVote":1,"tweetType":1,"viewCount":3306,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3478324697411284","authorId":"3478324697411284","name":"超股","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"idStr":"3478324697411284","authorIdStr":"3478324697411284"},"content":"你还看好这只股？？","text":"你还看好这只股？？","html":"你还看好这只股？？"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":956339198,"gmtCreate":1591574003714,"gmtModify":1704195947188,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/01317\">$枫叶教育(01317)$</a>不错不错，值得关注！","listText":"<a href=\"https://laohu8.com/S/01317\">$枫叶教育(01317)$</a>不错不错，值得关注！","text":"$枫叶教育(01317)$不错不错，值得关注！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/956339198","isVote":1,"tweetType":1,"viewCount":1999,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":910518949,"gmtCreate":1576044352981,"gmtModify":1704271128751,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/00763\">$中兴通讯(00763)$</a>同为5g概念你为啥不知道涨？看看人家立讯精密！！！","listText":"<a href=\"https://laohu8.com/S/00763\">$中兴通讯(00763)$</a>同为5g概念你为啥不知道涨？看看人家立讯精密！！！","text":"$中兴通讯(00763)$同为5g概念你为啥不知道涨？看看人家立讯精密！！！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/910518949","isVote":1,"tweetType":1,"viewCount":4174,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3537045207544484","authorId":"3537045207544484","name":"27个优质股","avatar":"https://static.tigerbbs.com/fde1daa28cae792e520759bac55bcdd3","crmLevel":2,"crmLevelSwitch":0,"idStr":"3537045207544484","authorIdStr":"3537045207544484"},"content":"大家的所属领域不同，立讯精密是零配件处在行业的顶端，中兴通讯是成品是通信应用处于行业的中游","text":"大家的所属领域不同，立讯精密是零配件处在行业的顶端，中兴通讯是成品是通信应用处于行业的中游","html":"大家的所属领域不同，立讯精密是零配件处在行业的顶端，中兴通讯是成品是通信应用处于行业的中游"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":903994963,"gmtCreate":1556785820852,"gmtModify":1704801148167,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"$特斯拉(TSLA)$ 融资的费率到底是多少？在哪里查？印象中好像是8%多？请教下大家！","listText":"$特斯拉(TSLA)$ 融资的费率到底是多少？在哪里查？印象中好像是8%多？请教下大家！","text":"$特斯拉(TSLA)$ 融资的费率到底是多少？在哪里查？印象中好像是8%多？请教下大家！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/903994963","isVote":1,"tweetType":1,"viewCount":2275,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":975665311,"gmtCreate":1600691907433,"gmtModify":1703822109336,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"本来以为卖了美股就安全了，可是其他a股h也下跌啊","listText":"本来以为卖了美股就安全了，可是其他a股h也下跌啊","text":"本来以为卖了美股就安全了，可是其他a股h也下跌啊","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/975665311","repostId":"1124902004","repostType":4,"isVote":1,"tweetType":1,"viewCount":2986,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":906921608,"gmtCreate":1558589407404,"gmtModify":1704696895863,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"$特斯拉(TSLA)$ 150我的蚂蚁花呗都要被炸出来了！","listText":"$特斯拉(TSLA)$ 150我的蚂蚁花呗都要被炸出来了！","text":"$特斯拉(TSLA)$ 150我的蚂蚁花呗都要被炸出来了！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/906921608","isVote":1,"tweetType":1,"viewCount":3285,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":354661149,"gmtCreate":1617167599781,"gmtModify":1617167599781,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"不错","listText":"不错","text":"不错","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/354661149","repostId":"1168244531","repostType":2,"repost":{"id":"1168244531","kind":"news","pubTimestamp":1617112248,"share":"https://ttm.financial/m/news/1168244531?lang=&edition=full","pubTime":"2021-03-30 21:50","market":"sh","language":"zh","title":"张一鸣内部演讲：字节应该回归 “平常心”","url":"https://stock-news.laohu8.com/highlight/detail?id=1168244531","media":"晚点LatePost","summary":"今天上午 10 点，字节跳动在启用不到半年的新办公地点北京方恒时尚中心举办九周年庆，张一鸣通过视频直播向全公司发表演讲，主题是平常心。\n字节跳动刚从小米挖来的 CFO 周受资也在活动中首次亮相。但他并","content":"<p>今天上午 10 点，字节跳动在启用不到半年的新办公地点北京方恒时尚中心举办九周年庆，张一鸣通过视频直播向全公司发表演讲，主题是平常心。</p>\n<p>字节跳动刚从小米挖来的 CFO 周受资也在活动中首次亮相。但他并未提到字节的上市计划或估值相关的信息。</p>\n<p>近一小时的主旨演讲中，张一鸣将所有时间用来强调团队应当保持平常心。他认为，团队越急切越紧张效果越不好，只有保持平常心，才能细腻地观察事物，做到不扭曲，定出比较好的目标和策略，做到比较好的执行结果。</p>\n<p>说这话时，根据彭博社本周的报道，字节跳动估值已经达到了 2500 亿美元，比去年 11 月最新一轮融资后高出 700 亿美元，也高于百度和快手市值之和。</p>\n<p>字节员工手里的期权也更值钱了。记者获悉，去年 6 月时，字节跳动回购员工期权的价格是每股 60 美元。11 月的融资后，每股回购价涨至 88 美元。而本月初，回购价格已涨到 180 美元。</p>\n<p>伴随估值提升，不断有字节国内或国际业务拆分上市的消息传出。财富激增的可能性从来都不利于让员工保持平常心。</p>\n<p>但字节的竞争对手比以往更多了。张一鸣称 2020 年是 “加速动态的一年”。一年里，字节增加了 4 万员工，在游戏、电商、教育等领域全线扩张。最近，抖音又开始尝试本地生活广告，进入美团的领地。</p>\n<p>字节今日头条和抖音的用户量增长不可能无限持续。而投入巨大的电商、教育和游戏业务，还没有展现出抖音、头条曾经的增长速度。</p>\n<p>近一小时的演讲中，张一鸣将所有时间用来强调团队应当保持平常心。</p>\n<p><b>有突破的业务：懂车帝、番茄小说、瓜瓜龙等</b></p>\n<p>演讲开始，张一鸣列出有进展的业务包括：懂车帝、番茄小说、头条搜索、瓜瓜龙启蒙、大力智能、飞书、朝夕光年。</p>\n<p>大力智能是字节教育部门的硬件产品，朝夕光年则是字节的游戏研发与发行团队。懂车帝平台内容、瓜瓜龙启蒙获得了用户较高的评价。他对番茄小说的原创内容表达了认可，去年十二月的双月会上，他还称赞过番茄小说的用户增长速度。同时他认为飞书的视频会议功能和头条的搜索功能比刚上线时都有了较大起色。</p>\n<p>字节跳动海外的增长也没有因为特朗普的总统令停下。根据张一鸣展示的增长曲线，即便去掉被封的 TikTok 印度数字，其海外产品日均活跃用户（DAU）增速，依然超过抖音、西瓜、今日头条等产品在中国的表现。</p>\n<p><b>团队应该谨慎下判断</b></p>\n<p>张一鸣说，团队很多时候并不清楚业务为什么增长或下滑。人们往往看到用户增长，就觉得自己做的对，不增长就非常焦虑。“增长可能是 UG（用户增长）花的钱多，可能是疫情隔离，用户降低可能是因为开学，这些和事情的本质没有多大的变化。” 所以增长的真正原因，“我们有时也不清楚。”</p>\n<p>张一鸣认为正确的决策来源于事实的观察，比起 “Rush to conclusion”，员工需要去体验产品、与用户交谈、理解自己的对手和处境，他举了两个字节早期的例子：</p>\n<p>在 2015 年前后、抖音还没上线时，字节内部曾讨论，快手是不是中国的 Instagram。但回头看，他觉得还是应该理解用户为什么用快手，而不是给它下定义。</p>\n<p>刚开始做抖音时，张一鸣和团队都相信城市用户留存不好的原因是，“白领脑力劳动多，不太会表演”。而 Musical.ly 的创始人 Alex 朱骏也认为，“中国（城市用户）工作多，压力大，没有时间表演”，并因此选择从美国起步。但现在来看，结果完全不是如此。</p>\n<p><b>团队不应该过度关注竞争</b></p>\n<p>随着字节进入越来越多的领域，它也有了越来越多的竞争对手。张一鸣称竞争对手就像蓝军，是参照。但他也警告说，竞争压力可能导致的行为变形，公司和员工被 “竞争干扰了注意力，内心被对于竞争的担忧占据了，” 反而做出了错误的决定。</p>\n<p>他用自己曾经任职的微软举例。微软的主要商业模式是服务企业客户，但 Google 崛起后，微软在浏览器、手机操作系统和 Google 全面竞争。此间，亚马逊悄悄孵化了针对企业的云计算生意，当微软回过神来，已经追赶不上。</p>\n<p><b>要有耐心做更伟大的产品</b></p>\n<p>压力之下，他希望员工能沉下心，换一种方式看待字节的产品，他举出了三个产品作为参照：Google Earth、Scratch（儿童编程软件）、Roblox（沙盒游戏）。这些产品不一定赚钱，但是 “有意思并且很伟大 “。他希望员工能 “remain grounded, keep aiming higher”.</p>\n<p>这三个产品的历史都比字节久远地多。Scratch 和 Roblox 都始于 2006 年，Google Earth 始于 2001 年。Scratch 是麻省理工媒介实验室开发的可视化儿童编程平台，产品开源免费。当中只有 Roblox 获得丰厚商业回报（去年收入 9.2 亿美元）。</p>\n<p><b>不要随便说 All In</b></p>\n<p>字节 2020 年收入超过 2200 亿元人民币，大约是百度的两倍。在讲话中，张一鸣提醒团队，在有资源之后，也不应轻易加杠杆，在错误的方向大投入。“很多公司，包括创业公司，会说咱们是不是就抓住这个机会、赌一把，All In。我自己觉得，随便说 All In 的公司有很大问题。“他认为，想要 All in 换句话说就是 “我不想了，就这样赌一把。”</p>\n<p><b>不要给自己打标签</b></p>\n<p>张一鸣提到了自己对 “打工人” 标签的反感。他认为设标签其实是对自身设限。他回忆自己的早期经历，说自己经常是 “老板不急，我急”，会做很多不在工作范围内的事情，并因此得到成长。</p>\n<p><b>说人话，不要用 fancy 的文档</b></p>\n<p>“过去我们主要靠推荐技术赋予的信息分发能力，跨端联动头抖西多个产品自研，实现深度共建，形成组合拳，打造内容生态闭环，以此赋能客户、用户，创造价值。未来我们要增加横向不同场景的价值，延长服务链路。”</p>\n<p>这是张一鸣在现场读的一段字节双月会的记录，作为不说人话的反面例子。他观察到，自己的内部的报告中，这种方法论、词汇越来越多。</p>\n<p>报告堆砌术语是典型的官僚作风。就像演讲中举的大部分例子一样，张一鸣一次次提醒自己的 10 万员工，不要患上大公司病，要在没有终止的竞争中保持活力。</p>","source":"wandian","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>张一鸣内部演讲：字节应该回归 “平常心”  </title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n张一鸣内部演讲：字节应该回归 “平常心”  \n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-30 21:50 北京时间&nbsp;&nbsp;&nbsp;<a href=https://mp.weixin.qq.com/s?__biz=MzU3Mjk1OTQ0Ng==&mid=2247487970&idx=2&sn=08a8a4ec6c55cf4fbd25e4d50d78372e&chksm=fcc9ae5bcbbe274d203bf6999b9710ea6c6158def681e05a2c0815d173ac069cf02e3016bd6c&scene=0&xtrack=1><strong>晚点LatePost</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>今天上午 10 点，字节跳动在启用不到半年的新办公地点北京方恒时尚中心举办九周年庆，张一鸣通过视频直播向全公司发表演讲，主题是平常心。\n字节跳动刚从小米挖来的 CFO 周受资也在活动中首次亮相。但他并未提到字节的上市计划或估值相关的信息。\n近一小时的主旨演讲中，张一鸣将所有时间用来强调团队应当保持平常心。他认为，团队越急切越紧张效果越不好，只有保持平常心，才能细腻地观察事物，做到不扭曲，定出比较好...</p>\n\n<a href=\"https://mp.weixin.qq.com/s?__biz=MzU3Mjk1OTQ0Ng==&mid=2247487970&idx=2&sn=08a8a4ec6c55cf4fbd25e4d50d78372e&chksm=fcc9ae5bcbbe274d203bf6999b9710ea6c6158def681e05a2c0815d173ac069cf02e3016bd6c&scene=0&xtrack=1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/fc0d9459911bfb890663ce7587256aa0","relate_stocks":{},"source_url":"https://mp.weixin.qq.com/s?__biz=MzU3Mjk1OTQ0Ng==&mid=2247487970&idx=2&sn=08a8a4ec6c55cf4fbd25e4d50d78372e&chksm=fcc9ae5bcbbe274d203bf6999b9710ea6c6158def681e05a2c0815d173ac069cf02e3016bd6c&scene=0&xtrack=1","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1168244531","content_text":"今天上午 10 点，字节跳动在启用不到半年的新办公地点北京方恒时尚中心举办九周年庆，张一鸣通过视频直播向全公司发表演讲，主题是平常心。\n字节跳动刚从小米挖来的 CFO 周受资也在活动中首次亮相。但他并未提到字节的上市计划或估值相关的信息。\n近一小时的主旨演讲中，张一鸣将所有时间用来强调团队应当保持平常心。他认为，团队越急切越紧张效果越不好，只有保持平常心，才能细腻地观察事物，做到不扭曲，定出比较好的目标和策略，做到比较好的执行结果。\n说这话时，根据彭博社本周的报道，字节跳动估值已经达到了 2500 亿美元，比去年 11 月最新一轮融资后高出 700 亿美元，也高于百度和快手市值之和。\n字节员工手里的期权也更值钱了。记者获悉，去年 6 月时，字节跳动回购员工期权的价格是每股 60 美元。11 月的融资后，每股回购价涨至 88 美元。而本月初，回购价格已涨到 180 美元。\n伴随估值提升，不断有字节国内或国际业务拆分上市的消息传出。财富激增的可能性从来都不利于让员工保持平常心。\n但字节的竞争对手比以往更多了。张一鸣称 2020 年是 “加速动态的一年”。一年里，字节增加了 4 万员工，在游戏、电商、教育等领域全线扩张。最近，抖音又开始尝试本地生活广告，进入美团的领地。\n字节今日头条和抖音的用户量增长不可能无限持续。而投入巨大的电商、教育和游戏业务，还没有展现出抖音、头条曾经的增长速度。\n近一小时的演讲中，张一鸣将所有时间用来强调团队应当保持平常心。\n有突破的业务：懂车帝、番茄小说、瓜瓜龙等\n演讲开始，张一鸣列出有进展的业务包括：懂车帝、番茄小说、头条搜索、瓜瓜龙启蒙、大力智能、飞书、朝夕光年。\n大力智能是字节教育部门的硬件产品，朝夕光年则是字节的游戏研发与发行团队。懂车帝平台内容、瓜瓜龙启蒙获得了用户较高的评价。他对番茄小说的原创内容表达了认可，去年十二月的双月会上，他还称赞过番茄小说的用户增长速度。同时他认为飞书的视频会议功能和头条的搜索功能比刚上线时都有了较大起色。\n字节跳动海外的增长也没有因为特朗普的总统令停下。根据张一鸣展示的增长曲线，即便去掉被封的 TikTok 印度数字，其海外产品日均活跃用户（DAU）增速，依然超过抖音、西瓜、今日头条等产品在中国的表现。\n团队应该谨慎下判断\n张一鸣说，团队很多时候并不清楚业务为什么增长或下滑。人们往往看到用户增长，就觉得自己做的对，不增长就非常焦虑。“增长可能是 UG（用户增长）花的钱多，可能是疫情隔离，用户降低可能是因为开学，这些和事情的本质没有多大的变化。” 所以增长的真正原因，“我们有时也不清楚。”\n张一鸣认为正确的决策来源于事实的观察，比起 “Rush to conclusion”，员工需要去体验产品、与用户交谈、理解自己的对手和处境，他举了两个字节早期的例子：\n在 2015 年前后、抖音还没上线时，字节内部曾讨论，快手是不是中国的 Instagram。但回头看，他觉得还是应该理解用户为什么用快手，而不是给它下定义。\n刚开始做抖音时，张一鸣和团队都相信城市用户留存不好的原因是，“白领脑力劳动多，不太会表演”。而 Musical.ly 的创始人 Alex 朱骏也认为，“中国（城市用户）工作多，压力大，没有时间表演”，并因此选择从美国起步。但现在来看，结果完全不是如此。\n团队不应该过度关注竞争\n随着字节进入越来越多的领域，它也有了越来越多的竞争对手。张一鸣称竞争对手就像蓝军，是参照。但他也警告说，竞争压力可能导致的行为变形，公司和员工被 “竞争干扰了注意力，内心被对于竞争的担忧占据了，” 反而做出了错误的决定。\n他用自己曾经任职的微软举例。微软的主要商业模式是服务企业客户，但 Google 崛起后，微软在浏览器、手机操作系统和 Google 全面竞争。此间，亚马逊悄悄孵化了针对企业的云计算生意，当微软回过神来，已经追赶不上。\n要有耐心做更伟大的产品\n压力之下，他希望员工能沉下心，换一种方式看待字节的产品，他举出了三个产品作为参照：Google Earth、Scratch（儿童编程软件）、Roblox（沙盒游戏）。这些产品不一定赚钱，但是 “有意思并且很伟大 “。他希望员工能 “remain grounded, keep aiming higher”.\n这三个产品的历史都比字节久远地多。Scratch 和 Roblox 都始于 2006 年，Google Earth 始于 2001 年。Scratch 是麻省理工媒介实验室开发的可视化儿童编程平台，产品开源免费。当中只有 Roblox 获得丰厚商业回报（去年收入 9.2 亿美元）。\n不要随便说 All In\n字节 2020 年收入超过 2200 亿元人民币，大约是百度的两倍。在讲话中，张一鸣提醒团队，在有资源之后，也不应轻易加杠杆，在错误的方向大投入。“很多公司，包括创业公司，会说咱们是不是就抓住这个机会、赌一把，All In。我自己觉得，随便说 All In 的公司有很大问题。“他认为，想要 All in 换句话说就是 “我不想了，就这样赌一把。”\n不要给自己打标签\n张一鸣提到了自己对 “打工人” 标签的反感。他认为设标签其实是对自身设限。他回忆自己的早期经历，说自己经常是 “老板不急，我急”，会做很多不在工作范围内的事情，并因此得到成长。\n说人话，不要用 fancy 的文档\n“过去我们主要靠推荐技术赋予的信息分发能力，跨端联动头抖西多个产品自研，实现深度共建，形成组合拳，打造内容生态闭环，以此赋能客户、用户，创造价值。未来我们要增加横向不同场景的价值，延长服务链路。”\n这是张一鸣在现场读的一段字节双月会的记录，作为不说人话的反面例子。他观察到，自己的内部的报告中，这种方法论、词汇越来越多。\n报告堆砌术语是典型的官僚作风。就像演讲中举的大部分例子一样，张一鸣一次次提醒自己的 10 万员工，不要患上大公司病，要在没有终止的竞争中保持活力。","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":2138,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":351885004,"gmtCreate":1616584915408,"gmtModify":1616584915408,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"文章说q1今年收入1千万","listText":"文章说q1今年收入1千万","text":"文章说q1今年收入1千万","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/351885004","repostId":"2120700679","repostType":2,"repost":{"id":"2120700679","kind":"news","pubTimestamp":1615930509,"share":"https://ttm.financial/m/news/2120700679?lang=&edition=full","pubTime":"2021-03-17 05:35","market":"us","language":"en","title":"Kindred Biosciences (KIN) Reports Q4 Loss, Lags Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2120700679","media":"Zacks","summary":"Kindred Biosciences (KIN) came out with a quarterly loss of $0.28 per share versus the Zacks Consens","content":"<html><body><p>Kindred Biosciences (KIN) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.40 per share a year ago. These figures are adjusted for non-recurring items.</p>\n<p>This quarterly report represents an earnings surprise of 15.15%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.31 per share when it actually produced a loss of $0.31, delivering no surprise.</p>\n<p>Over the last four quarters, the company has surpassed consensus EPS estimates two times.</p>\n<p>Kindred Bio, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.95 million for the quarter ended December 2020, missing the Zacks Consensus Estimate by 0.94%. This compares to year-ago revenues of $1.4 million. The company has topped consensus revenue estimates two times over the last four quarters.</p>\n<p>The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.</p>\n<p>Kindred Bio shares have added about 13.7% since the beginning of the year versus the S&amp;P 500's gain of 5%.</p>\n<p><b>What's Next for Kindred Bio?</b></p>\n<p>While Kindred Bio has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?</p>\n<p>There are no easy answers to this key question, but <a href=\"https://laohu8.com/S/AONE\">one</a> reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.</p>\n<p>Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.</p>\n<p>Ahead of this earnings release, the estimate revisions trend for Kindred Bio was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.</p>\n<p>It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.33 on $11.9 million in revenues for the coming quarter and -$1.14 on $41.2 million in revenues for the current fiscal year.</p>\n<p>Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 29% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.</p>\n<br/>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. \nClick to get this free report\n<br/> \n<br/>\n<a href=\"https://laohu8.com/S/KIN\">Kindred Biosciences, Inc.</a> (KIN) : Free Stock Analysis Report\n<br/> \n<br/>\nTo read this article on Zacks.com click here.\n<br/> \n<br/>\nZacks Investment Research</body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kindred Biosciences (KIN) Reports Q4 Loss, Lags Revenue Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKindred Biosciences (KIN) Reports Q4 Loss, Lags Revenue Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-17 05:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/kindred-biosciences-kin-reports-q4-213509431.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Kindred Biosciences (KIN) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.40 per share a year ago. These figures ...</p>\n\n<a href=\"https://finance.yahoo.com/news/kindred-biosciences-kin-reports-q4-213509431.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/88Fg6KE6GPnh0zlh3tqRTA--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/9naTdeJlVMX28sdlDpLdrQ--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ac90b3d74679f6d01a122aa033d8a9a4","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/kindred-biosciences-kin-reports-q4-213509431.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2120700679","content_text":"Kindred Biosciences (KIN) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.40 per share a year ago. These figures are adjusted for non-recurring items.\nThis quarterly report represents an earnings surprise of 15.15%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.31 per share when it actually produced a loss of $0.31, delivering no surprise.\nOver the last four quarters, the company has surpassed consensus EPS estimates two times.\nKindred Bio, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.95 million for the quarter ended December 2020, missing the Zacks Consensus Estimate by 0.94%. This compares to year-ago revenues of $1.4 million. The company has topped consensus revenue estimates two times over the last four quarters.\nThe sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.\nKindred Bio shares have added about 13.7% since the beginning of the year versus the S&P 500's gain of 5%.\nWhat's Next for Kindred Bio?\nWhile Kindred Bio has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?\nThere are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.\nEmpirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.\nAhead of this earnings release, the estimate revisions trend for Kindred Bio was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.\nIt will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.33 on $11.9 million in revenues for the coming quarter and -$1.14 on $41.2 million in revenues for the current fiscal year.\nInvestors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 29% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. \nClick to get this free report\n \n\nKindred Biosciences, Inc. (KIN) : Free Stock Analysis Report\n \n\nTo read this article on Zacks.com click here.\n \n\nZacks Investment Research","news_type":1,"symbols_score_info":{"KIN":1}},"isVote":1,"tweetType":1,"viewCount":2225,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":351083321,"gmtCreate":1616545959663,"gmtModify":1616545959663,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"为啥这两只刚好是我买入的，目前浮亏一成了！","listText":"为啥这两只刚好是我买入的，目前浮亏一成了！","text":"为啥这两只刚好是我买入的，目前浮亏一成了！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/351083321","repostId":"2107260553","repostType":2,"repost":{"id":"2107260553","kind":"news","pubTimestamp":1611851471,"share":"https://ttm.financial/m/news/2107260553?lang=&edition=full","pubTime":"2021-01-29 00:31","market":"us","language":"en","title":"These 2 Penny Stocks Could Rally All the Way to $11, Say Analysts","url":"https://stock-news.laohu8.com/highlight/detail?id=2107260553","media":"TipRanks","summary":"At its January FOMC meeting, the Federal Reserve held interest rates steady – they are near rock-bot","content":"<div>\n<p>At its January FOMC meeting, the Federal Reserve held interest rates steady – they are near rock-bottom now, and to no one’s surprise, the Fed is keeping them there.\nFed Chairman Jerome Powell may ...</p>\n\n<a href=\"https://finance.yahoo.com/news/2-penny-stocks-could-rally-163111780.html\">Web Link</a>\n\n</div>\n","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>These 2 Penny Stocks Could Rally All the Way to $11, Say Analysts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThese 2 Penny Stocks Could Rally All the Way to $11, Say Analysts\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-01-29 00:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/2-penny-stocks-could-rally-163111780.html><strong>TipRanks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>At its January FOMC meeting, the Federal Reserve held interest rates steady – they are near rock-bottom now, and to no one’s surprise, the Fed is keeping them there.\nFed Chairman Jerome Powell may ...</p>\n\n<a href=\"https://finance.yahoo.com/news/2-penny-stocks-could-rally-163111780.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/94euyTCm3Fsmi1L1JkZXKQ--~B/aD00NTc7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://s.yimg.com/uu/api/res/1.2/G1wIt1b2ALiEE..QV7lnrw--~B/aD00NTc7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/tipranks_452/24d79aa4d3847ec06a89abac7fdc7612","relate_stocks":{"BLRX":"BioLine Rx"},"source_url":"https://finance.yahoo.com/news/2-penny-stocks-could-rally-163111780.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2107260553","content_text":"At its January FOMC meeting, the Federal Reserve held interest rates steady – they are near rock-bottom now, and to no one’s surprise, the Fed is keeping them there.\nFed Chairman Jerome Powell may have fed some market pessimism when he spoke after the meeting, and pointed out that unemployment, which has been rising in recent months. For market watchers seeking support, there is solace in the Fed’s monetary policy. The central bank is committed to buying $80 billion monthly in Treasury notes, and has put a rate increase on hold, likely until 2023.\nAt least one top strategist sees the current market environment in terms of opportunity. JPMorgan strategist Marko Kolanovic takes a bullish stance, writing, “We expect the global COVID pandemic to decline rapidly in the coming weeks. In fact, the pace of decline in new cases over the last 2 weeks is the highest on record both in the US and globally… Central Banks should remain accommodative given the elevated unemployment levels and over a decade of low inflation running below their targets… Short-term turmoil, such as the one this week, are opportunities to rotate from bonds to equities.”\nTaking this outlook into consideration, we set out to find exciting opportunities that won’t break the bank, namely penny stocks. These stocks, priced at $5 or less, offer investors some of the highest growth potential available in the market. There is risk here, too, as the ‘pennies’ are often priced low for a reason, so due diligence is essential.\nUsing TipRanks’ database, we identified two penny stocks that have earned a “Strong Buy” consensus rating from the analyst community. Not to mention each offers up massive upside potential, as some analysts seem them climbing to $11.\nBioLineRx, Ltd. (BLRX)\nWe’ll start with BioLineRx, a clinical stage biopharma company focused on developing new cancer treatments. Oncology is a major field for cutting edge biopharmas. Cancer is frequently deadly, and frequently resistant to current treatments – and those treatments themselves will frequently cause severe side effects in patients. BioLineRx has an active pipeline of drug candidates, but the most advanced is motixafortide, a synthetic peptide which has completed patient enrollment in a Phase 3 study on stem cell mobilization for autologous bone-marrow transplantation.\nThe drug is being studied for its efficacy in promoting the harvesting of bone marrow prior to the cancer treatment. Results from a pre-planned interim analysis showed ‘statistically significant evidence favoring treatment with motixafortide in the primary endpoint,’ evidence which was so significant that the enrollment was completed early, with 122 patients instead of 177. Stem cell mobilization, using motixafortide, is seen as the company’s most efficient path to registering the new drug for regulatory approval.\nBased on the potential of motixafortide and the $2.40 share price, some analysts think that now is the time to pull the trigger.\nCovering BLRX for Oppenheimer, 5-star analyst Mark Breidenbach noted, “Our thesis remains centered on motixafortide in stem cell mobilization, and we see a disconnect between the company’s market capitalization and motixafortide’s market opportunity as a stem cell mobilizer. Key GENESIS secondary endpoints are expected by mid-2021, and we see little risk heading into these data…”\nThe analyst added, “We believe results from the Phase 3 GENESIS trial could spur the majority of transplant physicians to choose BL-8040 over Mozobil to combine with G-CSF if the drug is approved. Upside to our thesis includes BL-8040 for use in other auto-HSCTs, allo-HSCTs, AML, and solid tumors. The company boasts a catalyst-rich, deep oncology pipeline that has attracted collaborations with Novartis, Merck, and Genentech.”\nGiven all of the above, Breidenbach rates BLRX as a Buy, and his $11 price target suggests a whopping 358% upside for the year ahead. (To watch Breidenbach’s track record, click here)\nThe rest of the Street appears to echo Breidenbach’s bullish sentiment. As it has racked up 3 Buys and no Holds or Sells, the consensus is unanimous: BLRX is a Strong Buy. Adding to the good news, the upside potential lands at ~428% based on the $12.67 average price target. (See BLRX stock analysis on TipRanks)\n\n\n\n\n\nKindred Biosciences (KIN)\nWhile most biotech companies focus on human medications, we are not the only market. Kindred biosciences is biopharmaceutical company in the veterinary market, developing biologic medications to improve the lives of our pets and working animals. The company describes its mission as ‘[bringing] to pets the same kinds of safe and effective medicines that human family members enjoy.’\nParvovirus (CPV) is a highly infectious, and highly lethal, viral disease affecting dogs. While vaccines are available, untreated cases can see upwards of 91% mortality. Kindred’s main pipeline drug, KIND-030 is under development as a treatment for this disease.\nCurrently, the drug candidate is following two paths in the development process – one for treatment of established infections, and one as a prophylactic preventative treatment for CPV. The prophylactic study has shown positive results, with treated dogs all avoiding infection, while all dogs in the placebo group developed parvovirus disease. KIND-030 also showed a mortality benefit when given as a treatment for infection. The drug candidate is in the pivotal study stage of development, the last before potential approval.\nLast month, Kindred announced that it had entered an agreement with Elanco Animal Health – a major manufacturer of veterinary medicines – for production of KIND-030.\nCantor analyst Brandon Folkes sees plenty of potential in Kindred, especially in the company’s agreement with Elanco.\n“A partnership with a leading animal health company, in this case Elanco, is exactly what the company needed, in our view. In our view, this validates KIN's new strategic approach, as a developer of drugs while seeking larger commercial partners. We believe that today's deal should reinforce to investors that there remains meaningful value in Kindred's pipeline, which could be realized over the next 12 to 18 months,” Folkes opined.\nKindred is also conducting studies of Tirnovetmab, or KIND-016, an antibody targeting IL31, in the treatment of atopic dermatitis in dogs. The pivotal efficacy study of this drug started in the last quarter of 2020. There is a potentially huge market for a successful dermatitis treatment for canines; in the last six years, there has been a 47% increase in vet visits for dogs with severe itchy skin, and the market is estimated at $900 million or more.\n“While 2020 has been a tough year for KIN stock, the company continues to have multiple shots on goal from its diversified pipeline that could reward investors from the current levels. With multiple readouts in 2021, and the renewed sole focus on development of its pipeline we expect 2021 could be a banner year for KIN should it be able to deliver on the promise of its pipeline, and in particular the atopic dermatitis portfolio,” the analyst summed up.\nTo this end, Folkes gives KIN an $11 price target, implying a 139% upside potential for 2021, and an Overweight (i.e. Buy) rating. (To watch Folkes’ track record, click here)\nKindred is another company with a unanimous Strong Buy analyst consensus, this one based on 5 recent Buy reviews. The stock has an average price target of $10.25, which suggests room for ~124% growth from the current trading price of $4.59. (See KIN stock analysis on TipRanks)\n\n\n\n\n\nTo find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.\nDisclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.","news_type":1,"symbols_score_info":{"BLRX":0.6,"KIN":0.9}},"isVote":1,"tweetType":1,"viewCount":2813,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":910208155,"gmtCreate":1575964724877,"gmtModify":1704730216094,"author":{"id":"3464149602391943","authorId":"3464149602391943","name":"Dorash","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3464149602391943","authorIdStr":"3464149602391943"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$</a>为啥股价还没有起色？","listText":"<a href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$</a>为啥股价还没有起色？","text":"$小米集团-W(01810)$为啥股价还没有起色？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/910208155","isVote":1,"tweetType":1,"viewCount":2079,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}